MBIO News and Press, Mustang Bio Inc. From 05/19/22

Mustang Bio (NASDAQ:MBIO) said on Thursday treatment with its lentiviral gene therapy, MB-107, for X-linked severe combined immunodeficiency (XSCID) in newly diagnosed infants under the age of two support plans to begin a Phase 2 trial in the second half of this year. The data includes 2...

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented at the 25 th Annual Meeting of the American Society of Gene & Ce...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Mustang Bio press release (NASDAQ:MBIO): Q1 GAAP EPS of -$0.20. As of March 31, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $123.2 million, compared to $110.6 million as of December 31, 2021, an increase of $12.6 million year-to-date. For further details see...

WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, soli...

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., May 12, 2022 (GLOBE NEWSWI...

Last year was a productive year for Mustang Bio as they advanced the company’s cell and gene therapies deeper into clinical development. Recent figures from their CAR-T programs have revealed striking results that indicate potential cures for hematologic cancers and solid tumor...

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to date Seventeen of 18 patients with follow-up greater than 6 months achieved robust immune reconstitution All 23 treated...

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who received prior CD19-directed CAR T therapy Expect to dose first patient in multicenter...

WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...